Clarity Genomics uses well-established and state-of-art algorithms for integrative analysis of host-microbiome data to provide valuable interpretations for clinical research. We support translational and clinical development programs leveraging the therapeutic and diagnostic potential of the host microbiome. Academic collaborations with world-leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.
With access to a manually curated database of thousands of human metagenomes and involvement in large-scale collaboration projects including the American Gut Project, the Earth Microbiome Project and the NIH Human Microbiome Project, Clarity Genomics leverages its data aggregation potential for smarter diagnostics across different microbial ecosystems.
Secure Cloud Data Analysis
Clarity Genomics leverages secure cloud computing for high-throughput DNA sequencing and untargeted metabolomics data analysis. Analysis reports include security and privacy compliance in accordance with HIPPA, and reproducibility and documentation for CLIA compliance.
The goal of human microbiome research is to understand how human microbiota communicate with their host and factors that influence these interactions in health and disease. An imbalance in human microbiome structure or metabolic activity has been observed in many diseases including inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, obesity, and cancer. Moreover, host genetic variation can influence microbiome composition and provide valuable information on therapeutics response. Integrative analysis of multiple data types (proteins, genes, metabolites, biomarkers, clinical metadata, etc.) can provide high-resolution understanding of mechanisms governing host-microbiome interactions under different conditions.
Clarity Genomics in the News
Johnson & Johnson Innovation Announces New Collaborations Advancing Ground-Breaking Biomedical Innovation Around the Globe
NEW BRUNSWICK, N.J., June 15, 2017 /PRNewswire/ -- Johnson & Johnson Innovation LLC today announced new collaborations that seek to develop potential treatments for diseases in urgent need of solutions, including obesity and related complications, such as type 2 diabetes and non-alcoholic steatohepatitis (NASH), and rheumatoid arthritis, and advance cutting-edge technologies, including 3-D printing to create customized health solutions.